All In Biotech

Drug Trial Radar · NCT05988008

A Study of CCX168 in Japanese and Caucasian Healthy Adult Males

A Phase I Clinical Study of CCX168 in Japanese and Caucasian Healthy Adult Males

Last checked: Nov 20, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Oct 23, 2017

Primary completion

Jan 26, 2018

Study completion Sep 20, 2018

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objectives of the study will be to investigate the safety and pharmacokinetics of a single oral administration and a twice-daily multiple oral administration of CCX168 in Japanese healthy adult males; and to compare the pharmacokinetics of a single oral administration and a twice-daily multiple oral administration of CCX168 between Japanese and Caucasian healthy adult males.

Conditions

  • Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions

  • CCX168Drug

    Administered orally.

  • PlaceboDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse EventsTime frame: Up to 14 days
  2. Number of Participants Experiencing Adverse Drug ReactionsTime frame: Up to 14 days
  3. Number of Participants Experiencing Clinically Significant Changes in Vital Sign ParametersTime frame: Up to 14 days
  4. Number of Participants Experiencing Clinically Significant Changes in Electrocardiogram (ECG) ParametersTime frame: Up to 14 days
  5. Number of Participants Experiencing Clinically Significant Changes in Clinical Laboratory ParametersTime frame: Up to 14 days
  6. Maximum Plasma Concentration (Cmax) of CCX168Time frame: Up to 14 days
  7. Cmax of CCX168-M1 (Metabolite)Time frame: Up to 14 days
  8. Time of Cmax (tmax) of CCX168Time frame: Up to 14 days
  9. Tmax of CCX168-M1Time frame: Up to 14 days
  10. Area Under the Plasma Concentration Time Curve (AUC) from Time 0 to Infinity (AUC0-inf) of CCX168Time frame: Up to 14 days
  11. AUC0-inf of CCX168-M1Time frame: Up to 14 days
  12. AUC from Time 0 to Time of Last Measurable Plasma Concentration (AUC0-tz) of CCX168Time frame: Up to 14 days
  13. AUC0-tz of CCX168-M1Time frame: Up to 14 days
  14. AUC During a Dosing Interval of CCX168Time frame: Cohorts B and D only: Up to Hour 12 post-dose on Days 1 - 7
  15. AUC During a Dosing Interval of CCX168-M1Time frame: Cohorts B and D only: Up to Hour 12 post-dose on Days 1 - 7
  16. Terminal Elimination Half-life of CCX168Time frame: Up to 14 days
  17. Terminal Elimination Half-life of CCX168-M1Time frame: Up to 14 days
  18. Apparent Oral Clearance of CCX168Time frame: Up to 14 days
  19. Apparent Volume of Distribution During the Terminal Phase of CCX168Time frame: Up to 14 days
  20. Mean Residence Time to Infinity of CCX168Time frame: Up to 14 days
  21. Accumulation Ratio of CCX168Time frame: Cohorts B and D only: Up to 14 days
  22. Accumulation Ratio of CCX168-M1Time frame: Cohorts B and D only: Up to 14 days
  23. Trough Plasma Concentration at the End of Dosing Interval of CCX168Time frame: Cohorts B and D only: Up to 14 days
  24. Trough Plasma Concentration at the End of Dosing Interval of CCX168-M1Time frame: Cohorts B and D only: Up to 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sumida Hospital, SOUSEIKAI Global Clinical Research Center

    Sumida City, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.